The data showed the benefits of Abbott's TriClip for tricuspid regurgitation, MitraClip for treating mitral regurgitation, Amulet for stroke reduction and Portico for aortic stenosis
Abbott presented data from five late-breaking presentations demonstrating the advantages of Abbott's minimally invasive devices. (Credit: Abbott)
Abbott presented data from five late-breaking presentations demonstrating the advantages of the company’s minimally invasive devices in treating patients with a variety of structural heart diseases.
The data were presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific meeting of the Cardiovascular Research Foundation in Boston.
In the results, the transcatheter edge-to-edge repair (TEER) device, MitraClip, was found to be valuable in treating leaking valves in mitral regurgitation (MR) patients.
The data showed the benefits of Abbott’s TriClip, the first therapy specifically designed for tricuspid heart valve repair.
Results of the Amplatzer Amulet Left Atrial Appendage Occluder, for complete closure of the left atrial appendage (LAA) to lower the risk of stroke, and Portico, a self-expanding transcatheter aortic valve implantation (TAVI) system, were also presented.
The data from the prospective, multi-centre, worldwide real-world EXPAND G4 trial backed the safety and efficacy of the MitraClip G4 system for treating MR.
With more than 1,000 patients, the statistics show that MitraClip has success rates for reducing MR, enhancing the quality of life, and having low rates of side events.
After 30 days, the trial saw MR reduction to mild or less in 91% of patients with the lowest reported adverse event rates.
Abbott reported data from the TRILUMINATE Pivotal trial which evaluated the safety and efficacy of TEER with TriClip in 700 patients with severe TR in the US, Canada, and Europe.
The results from the roll-in cohort indicated a high implant success rate (99%) after 30 days and one-grade TR reduction in 91% of patients, with moderate or less residual TR achieved in 74%.
The firm also presented data of 1,800 patients from its prospective, multicentre, multinational Amulet IDE trial that supported the use of its Amplatzer Amulet.
According to Abbott’s three-year results, strokes in patients who had Boston Scientific’s Watchman as opposed to those who had Amulet were more commonly preceded by device-related thrombosis or peri-device leak.
The firm also noted that cardiovascular and all-cause mortality tended to be greater in the Watchman device compared to the Amulet device.
The data from the PREDICT-LAA prospective, multi-centre, randomised controlled trial were also presented which further supported the Amulet device.
At three months, Abbott said planning with FEops HEARTguide for high-resolution heart scans resulted in improved procedural efficiency and safety outcomes with the Amplatzer Amulet LAA Occluder.
The company also announced data from its CONFIDENCE Registry that evaluated the safety and effectiveness of Portico TAVI (transcatheter aortic valve implantation).